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 Cost Savings of Universal Decolonization to Prevent Intensive Care Unit 
Infection:  Implications of the REDUCE MRSA Trial 
 
Susan S.  Huang,  MD,  MPH;1  Edward  Septimus,  MD;2    Taliser R. Avery,  MPH;3   Grace  M.  Lee,  
MD,  MPH;3 Jason  Hickok,  MBA,  RN;4    Robert  A.  Weinstein,  MD;5    Julia  Moody,  MS;4    Mary K. 
Hayden,  MD;6 Jonathan  B.  Perlin, MD, PhD;4    Richard Platt, MD, MS;3    G.  Thomas Ray, MBA7 
 
OBJECTIVE.     To estimate  and compare  the  impact on  healthcare  costs of 3 alternative  strategies  for  
reducing  bloodstream  infections  in the intensive care unit (ICU): methicillin-resistant Staphylococcus aureus (MRSA) 
nares screening and isolation, targeted decolonization (ie, screening, isolation, and decolonization of MRSA carriers or 
infections), and universal decolonization (ie, no screening and decolonization of all ICU patients). 
DESIGN.     Cost analysis using decision modeling. 
METHODS. We developed a decision-analysis model to estimate the health care costs of targeted decolonization and 
universal decolonization strategies compared with a strategy of MRSA nares screening and isolation. Effectiveness 
estimates were derived from a recent randomized trial of the 3 strategies, and cost estimates were derived from the 
literature. 
RESULTS.  In the base case, universal decolonization was the dominant strategy and was estimated to have both lower 
intervention costs and lower total ICU costs than either screening and isolation or targeted decolonization. Compared 
with screening and isolation, universal decolonization was estimated to save $171,000 and prevent 9 additional 
bloodstream infections for every 1,000 ICU admissions. The dominance of universal decolonization persisted under a 
wide range of cost and effectiveness assumptions. 
CONCLUSIONS. A strategy of universal decolonization for patients admitted to the ICU would both reduce 
bloodstream infections and likely reduce healthcare costs compared with strategies of MRSA nares screening and 
isolation or screening and isolation coupled with targeted decolonization. 
 
The intensive care unit  (ICU)  has been a long-standing  focus of attention for reducing largely preventable 
healthcare- associated   infections.1· 3    Many   prevention   strategies   have emerged to reduce the 
prevalence or transmission of anti-biotic-resistant pathogens, such as methicillin-resistant Staphylococcus 
aureus (MRSA), as well as to reduce bloodstream infections (BSis). 4• 7  Several  of these strategies  have 
evidence of benefit in observational studies, but comparative effectiveness studies have only recently been 
published, and comparative cost analyses are  lacking.8• 11 
Recently, 3 promising strategies were compared in a large, cluster-randomized trial (the Randomized 
Evaluation of De- colonization versus Universal Clearance to Eliminate [REDUCE] MRSA trial).9 This 
43-hospital, 74-ICU trial com- pared the effectiveness of screening and isolation, targeted 
decolonization, and universal decolonization with respect to their ability to reduce the rate of MRSA-
positive clinical cultures and all-pathogen BSis in adults. "Screening and isolation" was the routine and 
long-standing strategy in these hospitals and consisted of screening all patients for  MRSA nasal 
colonization at admission to the ICU and using contact precautions for patients with current or previous 
MRSA colonization or infection.1 2  One-third of hospitals were randomized to initiate "targeted 
decolonization," which involved screening and isolation but added a 5-day decolonization regimen for 
all known MRSA carriers or patients with MRSA infection that consisted of twice-daily  intranasal  
mupirocin and daily bathing with chlorhexidine-impregnated cloths. Another third of hospitals were 
randomized to initiate "universal decolonization," in which ICU admission screening for MRSA was 
stopped, contact precautions were unchanged from the other strategies, and all patients received 
twice-daily intra- nasal mupirocin for 5 days plus daily bathing with chlorhexidine-impregnated 
cloths for the entire ICU stay. 
The results of the REDUCE MRSA trial indicated that universal decolonization was more 
effective than targeted de- colonization or screening and isolation in reducing BSis from any 
 pathogen. However, the cost implications of these strategies have not been addressed in light of 
these results. Our objective was to estimate the incremental effect on healthcare costs associated 
with targeted decolonization and universal decolonization compared with screening and isolation, 
which we considered to be the current standard of care. If either of these 2 strategies were found to 
be less costly than screening and isolation, the benefits of implementing one of these strategies 
would be to not only improve health but also decrease use of healthcare resources. 
 
METHODS 
Decision Analysis Model 
We developed a static decision analysis model, programmed in Microsoft Excel, that compared the 
effects of the above 3 strategies for preventing infections in adult ICUs: (1) screening and 
isolation, (2) targeted decolonization, and (3) universal decolonization (Table 1).9 
Using data from the REDUCE MRSA trial and cost and utilization estimates from published 
sources, we simulated the effects of each of the 3 strategies on healthcare costs, ICU days, and BSis 
for 1 year, assuming a hospital with 1,000 annual ICU admissions. Because the trial did not 
measure effects outside of the ICU, we only modeled ICU impact. The primary perspective was 
that of the healthcare system. Be- cause this was strictly a cost analysis, no quality-of-life measures 
were incorporated, nor were health states assigned dollar values. 
Model Inputs: Percentage of Patients Placed on Contact Precautions 
We assumed that the background percentage of patients who arrive at the ICU and have test results 
positive for MRSA or have a known recent history of MRSA infection or colonization was 11% 
(Table 2). This estimate was based on the ICU MRSA importation rate reported from the baseline 
period in all arms of the REDUCE MRSA trial,9 and it remained unchanged during the 
implementation phase for the arms that continued screening. For the universal decolonization arm, 
knowledge of MRSA importation decreased in the implementation phase to 4%, likely because of 
cessation of screening and possibly because of effects of decolonization for patients readmitted to 
the ICU. Therefore, under the universal decolonization strategy, fewer persons were modeled as 
being placed on contact precautions. For this cost analysis, it was not necessary to model the "true" 
percentage of patients colonized with MRSA or the relationship between MRSA colonization and 
the rate of BSI. The percentage of patients with test results positive for MRSA is primarily 
important in the model because it affects the number of persons who are placed on contact 
precautions and therefore affects costs. For the universal colonization strategy, 4% of patients  
were placed on contact precautions (and therefore incurred the associated costs) because they had 
some known history of MRSA colonization or infection, but this percentage should not be 
interpreted as directly relating to any "true" colonization rate. 
 
Model Inputs:  Risk of BSI 
Using data from the REDUCE MRSA trial, the baseline incidence of BSI was assumed to be 
19.63 cases per 1,000 ICU admissions, equivalent to approximately 5 infections per 1,000 ICU-
days (Table 2). The risk of BSI under the 3 different strategies was also derived from the REDUCE 
MRSA trial, which reported as-assigned adjusted hazard ratios of 0.98, 0.77, and 0.55 for the 
screening and isolation, targeted de- colonization, and universal decolonization strategies, 
respectively9.  These results were relative to the pre-trial time period, in which all arms were 
 performing screening and isolation. To compare the targeted decolonization and universal de- 
colonization strategies to screening and isolation, we adjusted the results of those strategies so as 
to be relative to the long- standing gold standard of screening and isolation. 11 This resulted in the 
relative risk of BSI being 1.00, 0.7857, and 0.5612 for the screening and isolation, targeted 
decolonization, and universal decolonization strategies, respectively. 
 
TABLE   1. Description  of  the Strategies  to  Prevent  Intensive  Care  Unit  (ICU)  Bloodstream  Infection  Considered  in  the Cost Analysis 
Strategy  Description 
Screening  and  isolation baseline strategy Universal  nares screening  for  MRSA  carriage  at  ICU  admission;  use  of contact precautions 
For MRSA carriers (by history or positive screening test result/clinical culture) 
Targeted decolonization Universal nares screening for MRSA carriage at ICU admission; use of contact precautions 
for MRSA carriers (by history or positive screening test result/clinical culture); decolonize 
MRSA carriers with daily chlorhexidine baths and mupirocin treatment 
Universal decolonization No screening for MRSA at admission to the ICU; use of contact precautions for MRSA 
carriers (by history or positive clinical culture); give daily chlorhexidine baths and 
mupirocin to all patients in ICU 
NOTE.     MRSA, methicillin-resistant Staphylococcus aureus. 
 
 
 
TABLE 2.  Decision-Analysis Model Inputs Derived from the REDUCE MRSA Trial: MRSA Colonization and Risk of 
Bloodstream Infection by Intensive Care Unit (ICU) Strategy 
Input parameter 
Patients arriving at ICU who test positive for MRSA colonization or who have known 
MRSA history, by ICU strategy 
Screening and isolation• 
Targeted decolonization' 
Universal decolonization 6 
Baseline risk of bloodstream infection (screening and isolation strategy) per 1,000 
ICU admissions 
Risk of any bloodstream infection, by strategy, relative to screening and isolationJ 
Screening and isolation 
Targeted decolonization 
Universal decolonization 
Base case Range 
 
 
11 5-20 
11 5-20 
4 4-20 
 
19.63' 5-30 
 
1.0000 
0.7857 0.6657-0.9157 
0.5612 0.4912-0.6512 
 
 
NOTE. Data are percentage of patients, unless otherwise indicated. MRSA, methicillin-resistant Staphylococcus aureus; 
REDUCE, Randomized Evaluation of Decolonization versus Universal Clearance to Eliminate. All estimates derived from 
Huang et al.9 
" Estimate  based  on  the average  baseline  values  reported  by Huang  et al.9 
" Estimate based on the trial results reported by Huang et al.9 This differs from the other strategies, because 
under the universal decolonization strategy, ICU screening was stopped and active decolonization was occurring for all 
patients. As the intervention progressed, patients who were readmitted may have been less likely to be identified as MRSA 
positive. Patients with an earlier ICU admission would be less likely to be screened for MRSA and less likely to acquire 
MRSA because of universal decolonization. In the trial, 47% of patients with a history of MRSA had a previous admission in 
the past year. The fact that this 4% value is lower than for the other 2 strategies does not imply anything about the “real" 
colonization rate. The only impact of this value on the cost results is that it means fewer persons are put on contact 
precautions under the strategy of universal decolonization. 
‘Equivalent to 4.99 bloodstream infections per 1,000 ICU-days. 
dIn  the  published  report  of  the  trial,9   the effectiveness  of  the strategies  was reported  relative  to the  baseline 
(preintervention ) period. We have here adjusted those results so as to make the screening and isolation strategy the reference. 
"Low" and “high” represent 95% confidence intervals. 
Model Inputs: Costs and ICU-Days 
Parameter estimates related to the base case are shown in Table 3. Intervention costs were derived 
from the literature. Intervention-related costs are the costs of screening, contact precautions, and 
decolonization. Where possible, preference was given to estimates that were more recent and were 
from the United States. The estimates used in most of the recent literature did not vary substantially, 
with the exception of the cost of an MRSA screening test and the cost of mupirocin. Variation in 
 screening costs were primarily related to whether the screening was assumed to be performed using 
the more costly polymerase chain reaction (PCR) test or the less costly chromogenic agar culture. 
Variation in literature estimates of the cost of mupirocin primarily related to whether generic or 
trade mupirocin was assumed to be used. In our base case, we assumed the chromogenic agar culture 
was used for screening (as it was in nearly all hospitals of the REDUCE MRSA trial) and that 
generic mupirocin was used for de- colonization. We also assumed that positive chromogenic agar 
cultures would not require confirmatory tests, and therefore we assumed no difference in screening 
costs between positive and negative screens. Any additional labor costs involved in applying 
mupirocin were assumed to be negligible, and be- cause patients are typically bathed at least once a 
day as part of usual care, we assumed that the cost of bathing with chlorhexidine cloths does not 
require any additional labor. Cost estimates reflect the "steady state;" we did not attempt to estimate 
start-up costs, such as those that might be associated with training staff. All cost estimates are in 
$US, adjusted to year 2012 using the consumer price index. 
We used estimates from the literature to estimate the incremental hospital days and cost of a BSI (and 
therefore the incremental savings associated with preventing an infection). Hassan et al1 3   estimated 
that the incremental hospital-days associated with a hospital-acquired infection (not specifically BSI) 
was 3.296. In  addition,  they  estimated  that  the cost  of an additional hospital-day  once  an  infection  
was  acquired was 24% higher than the cost of an uninfected day. Dasta et al1 6   estimated  that  the  
mean  cost  of  an  ICU-day  (after  day 3) was $4,385 (after adjusting to 2012 dollars). Applying the 
above estimates, we estimated the incremental cost of a BSI to be $17,920 (3.296   x   [4,385 + (0.24   
x   4,385)]).  This estimate is consistent with the estimated incremental cost of BSis reported by Kilgore 
et al25 ($22,371 in year 2012 dollars), who, like Hassan et al13, used a large US database and 
implemented methods to control for heterogeneity and endogeneity biases. All differences among the 3 
strategies in hospital days and general ICU costs (not including intervention costs) were assumed to be 
due entirely to differences in the incidence of BSis and their effects on length of stay and cost per day. 
To test the sensitivity of the model results, we varied several important parameters (baseline incidence 
of BSI, reduction in BSI associated with universal decolonization, and incremental ICU cost of BSI) over 
a wide range. In addition, we estimated the differences between the 3 screening strategies under a number 
of alternative scenarios to the base case. For example, we included a scenario in which the PCR test, 
rather than chromogenic culture, is used to test for MRSA, and a scenario in which trade, rather than 
generic, mupirocin   is used for decolonization. Another scenario included only those costs estimated to 
be variable in the short run. In their study of variable versus fixed costs of hospital care, Roberts et al'4 
treated labor and overhead as fixed in the short run and estimated that only 16% of all hospital costs 
(corresponding to healthcare worker supplies) were avoidable in the short run. Therefore, in this scenario, 
we assumed that the incremental cost of a BSI was 16% of our base case estimate, and we assumed no 
incremental cost for labor to don and doff gowns and gloves. 
  
 
 
TABLE 3.    Decision-Analysis Model Inputs and Literature Sources, Base Case Scenario 
 
Input parameter 
 
Base case 
Range for 
sensitivity analyses 
Sources for 
base  case, range 
Cost  of  screening  test ($) 9.12 9.12- 48.24 Fee schedule, fee schedule' 
Contact precautions    
Cost  per gown ($) 0.96  Kang et al" 
Cost  per  pair  of  gloves ($) 0.09  Kang et al" 
Time to don  and  doff gown  an d  gloves  (minutes) 1.00 1.00- 2.00 Kang et al" ;  Puzniak  et al" 
No.  of  nurse  visits  per  ICU patient-day" 53.00 30- 53 Kang et  al21;  Morgan  et al'" 
No.  of  physician  visits  per  ICU patient-day" 13.00 6- 13 Kang et  al21;  Morgan  et al" 
Hourly wage, nurses 34.24  Kang et al" 
Hourly  wage, physicians 89.46  Kang  et al21 
Total cost per day of contact  precautions I 18.84  Calculated 
Decolonization 
Cost of chlorhexidine impregnated cloths, 1 body wash ($) 
No. of daily baths with chlorhexidine cloths' 
Cost of twice-daily intranasal mupirocin for 5 days ($)d 
Incremental labor costs associated with decolonization ' 
ICU-days 
Mean ICU-days for patients with negative MRSA screen without bloodstream infection' 
Mean ICU-days for patients with positive MRSA screen without bloodstream infection' 
Incremental ICU-days for persons with bloodstream infection, but due to additional 
comorbidities rather than infection per se' 
Mean incremental ICU-days due to bloodstream infection' 
Cost per ICU-day, days without bloodstream infection ($)" 
Incremental cost per ICU-day for patients with bloodstream infection ($)' 
Total incremental cost of bloodstream infection ($)' 
 
5.35 
1.25 
7.32 
0.00 
 
4.15 
5.15 
3.46 
 
3.30 
4,385 
1,052 
17,920 
 
 
 
 
7.32- 93.92 
 
 
 
 
 
 
 
 
 
 
 
2,880-35,000 
 
Nelson et al" 
Assumption 
Courville24 
Assumption 
 
Trial data 
Trial data 
Hassan et al" 
 
Hassan et al" 
Dasta et al" 
Hassan et al”; Dasta et al"' 
Calculated; Roberts et al''; 
Kilgore and Brossette25 
 
NOTE. All  costs  are  in  $US  and  have  been  adjusted  to  the  2012  price  level  using  the  consumer  price  index.  ICU, intensive care unit; PCR, polymerase chain 
reaction. 
" Base case assumes screening culture using chromogenic agar, assuming no extra cost for a positive result. High-range cost assumes use of PCR screening 
test. Cost estimates are national limit reimbursement from 2013 US clinical diagnostic laboratory fee schedule, available at http://www.cms.gov/Medicare/ 
Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/clinlab,html, HCPCS 87081, "Culture screen only," and  HCPCS 87641 "Mr-staph dna amp probe." 
“Base case visit counts were based on direct observation of staff at 3 Department of Veterans Affairs hospitals and 1 university teach hospital." The actual 
observed mean physician visits per ICU-day was 17, but it was estimated that approximately 25% of these visits were associated with the teaching function of 
the hospitals (Daniel Morgan, personal communication). We therefore assumed 13 mean physician visits per day. 
' Assuming 1 bath per day as routine, plus 0.25 baths per day to account for large patients, incontinence, and wastage. 
" Base case assumes use of generic mupirocin.  High value is based on authors' analysis of average wholesale price for trade mupirocin. 
' Assume negligible additional labor time for applying mupirocin and that use of chlorhexidine cloths requires no additional time relative to normal bath.     
‘Estimates are from unpublished data from the Randomized Evaluation of Decolonization versus Universal Clearance to Eliminate [REDUCE] MRSA trial.' 
These lengths of stay were applied to the screening and isolation and targeted decolonization strategies. For universal decolonization, in which  patients are not 
screened for MRSA colonization, the length of stays were calibrated so as to be the same as stays in  the other  2 strategies, except for  any reductions caused 
by prevention  of bloodstream infections. 
' Estimates  reported  in  Hassan  et  al13   were for all hospital-acquired  infections  and  all  units.  We assumed  these would  apply to  bloodstream  infections that 
occurred  in  the ICU and  that  the additional  hospital-days  would be in the ICU. 
" Because we use this estimate for the incremental costs of additional days within a stay, we used the mean cost as reported by Dasta et al"' for days 3 and 
later. The  mean  cost  per ICU-day reported  by Dasta  et al16  was not specifically for  uninfected  days. However,  given  the relatively low incidence of hospital  - 
acquired  infections  (about 6% as reported  in  Hassan  et al" ), we treated  this as a  reasonable estimate for the cost of an  uninfected ICU-day. 
' Percentage  increase  (24% ) in  uninfected  cost  per  day as estimated  by Hassan  et al"  applied  to  estimated  cost  per  ICU-day  of  Dasta  et  al.'" 
' The low value of $2,880 is 16% of the base case estimate and is an estimate of short-run marginal costs that includes only healthcare worker supplies. 
 
 
  
TABLE  4.    Costs,  Length of Stay, and Cost Savings Associated  with 3 Intensive Care Unit  (ICU) Strategies 
to  Reduce  ICU  Bloodstream  Infection  per  1,000  ICU  Admissions,  Base Scenario 
  Strategy  
Baseline   
screening Targeted Universal 
Variable and isolation decolonization decolonization
ICU admissions    
Total  admissions  to ICU 1,000 1,000 1,000 
No. of patients screened for MRSA at admission 1,000 1,000 0 
No. of patients screening positive for  MRSA (or    
status is otherwise  known  at admission) llO 110 40 
No. of patients on  contact  precautions 110 110 40 
No.  of  patients decolonized 0 110 1,000 
No. of  patients with any bloodstream  infection 20 15 11 
ICU-days    
Total  no.  of ICU-days 4,391 4,377 4,362 
No. of patient-days  with contact precautions 581 579 209 
Costs ($)    
Cost of  MRSA screening  tests 9,120 9,120 0 
Cost  of contact precautions 69,010 68,830 24,890 
Cost  of decolonization 0 4,679 36,500 
ICU  costs, not  including screening, contact pre-    
cautions  and decolonization 19,320,000 19,250,000 19,170,000 
Total cost 19,400,000 19,330,000 19,230,000 
Total  cost  per admission 19,400 19,330 19,230 
Incremental costs (savings) per admission com- 
pared with screening and isolation  ($) 
Intervention  costs only (screening,  contact pre- 
cautions, decolonization) 
Bloodstream infection-related ICU  costs 
All costs 
Incremental costs (savings) per admission com- 
pared with screening and isolation  ($) 
Intervention  costs only (screening, contact pre- 
cautions, decolonization) 
Bloodstream infection-related ICU  costs 
All costs 
NOTE.      MRSA,  methicillin-resistant  Staphylococcus aureus. 
 
 
 
 
4 
(75) 
(71) 
 
 
 
( 17) 
(155) 
(171) 
 
 
 
(21) 
(79) 
(100) 
 
 
RESULTS 
Over the course of l year at a hospital with 1,000 annual adult ICU admissions, we estimated that a 
strategy of universal decolonization would prevent 9 BSis compared with a strategy of screening and 
isolation (11 vs 20) and 4 BSis compared with a strategy of targeted decolonization (11 vs15; Table 
4). The universal decolonization strategy was estimated to have the lowest mean intervention costs, 
saving $17 per admission compared with screening and isolation and saving $21 per admission 
compared with targeted decolonization. By preventing BSis, the universal decolonization strategy 
was estimated to save $155 per admission in non-intervention, ICU-related costs compared with 
targeted de- colonization. In total, for every ICU admission, universal decolonization was estimated 
to save $171 compared with screening and isolation and $100 compared with targeted 
decolonization. 
These results were robust to changes in the parameter estimates that were derived from the 
REDUCE MRSA trial.9 Figure lA shows the estimated savings per admission (com- pared with 
screening and isolation) of universal decolonization, assuming it was less effective at preventing 
BSis than was reported in the REDUCE MRSA trial. Because the strategy 
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FIGURE 1. One-way sensitivity analyses of the estimated cost savings of universal decolonization compared with screening and isolation per 
intensive care unit (ICU) admission when evaluating (A) the relative reduction (risk ratio) in bloodstream infections, (B) the baseline 
incidence of ICU bloodstream infections, and ( C) the incremental cost of an ICU bloodstream infection. 
 
of universal decolonization was estimated to have lower intervention costs than strategies involving 
screening, we estimated there would be modest cost savings even if it were not more effective in 
preventing BSis than screening and isolation alone. Results were also robust to varying assumptions 
regarding the baseline incidence of ICU BSis (Figure lB) and to the incremental  cost of a BSI 
(Figure  IC). 
We estimated the differences between the 3 screening strategies under a number of alternative 
scenarios to the base case (Table 5). Results were robust to a large number of plausible alterations in 
the assumptions. For example, if the more costly PCR test is used for MRSA screening, the universal 
decolonization strategy saves $210 per ICU admission versus $171 if chromogenic agar culture is 
used (scenario 1). If the more costly trade mupirocin is used for decolonization, the universal 
decolonization strategy saves $85 per ICU admission versus $171 if generic mupirocin is used 
(scenario 2). When including only costs estimated to be avoidable in  the short-term (ie, when all 
labor is considered to be a "fixed" cost in the time period under consideration), universal 
decolonization saves $23 per ICU admission (scenario Ml) compared with screening and isolation. 
Only under the most pessimistic combination of assumptions did the universal colonization strategy 
cost more than the other  two strategies. 
 
 DISCUSSION 
Universal decolonization has been shown to be a more effective strategy for reducing BSis due to all 
pathogens than either MRSA screening and isolation or MRSA screening plus targeted decolonization ! 
We now show that universal de- colonization is also likely to reduce costs. Because savings come 
both from reductions in BSis (and associated ICU savings) and from lower intervention costs, the 
benefits of universal decolonization are robust across a wide range of plausible  cost  and  
effectiveness  assumptions.  Consistent with 
other studies,15  we also found that a strategy of screening and targeted decolonization , although not 
as cost-beneficial as universal decolonization, also resulted in lower costs and fewer BSis than 
screening and isolation alone. 
For a hospital with 1,000 ICU admissions per year, we estimate that universal decolonization 
would prevent 9 BSis and potentially save approximately $171,000 annually com- pared with 
screening and isolation. The majority of the estimated savings ($155,000) are associated with 
expected reductions in BSis. Because the combined cost of chlorhex-idine-impregnated cloths and 
generic mupirocin is similar to the cost of screening  cultures,  the  balance  of  the savings 
($17,000) is primarily related to savings from reducing the number of patients placed on contact 
precautions. Using our base case cost assumptions, intervention costs will be similar under both 
strategies only if the percentage of patients placed on contact precautions is similar, which is highly 
unlikely given the lack of screening testing under universal decolonization, or if we assume no 
incremental labor costs for donning gloves and gowns. 
A strategy of universal decolonization has been shown to reduce BSis by over 40%,9 and most of 
the savings from implementing that strategy would come from reducing BSis and  the associated  
ICU-days. The magnitude of the actual savings at any given institution will largely depend on the 
ability to realize cost reductions from fewer infections. Using estimates from the literature, we assumed 
that each infection prevented   would   avert   3.3 ICU-days and   potentially save $18,000. The estimated 
cost per ICU-day that we used was based on hospital charges that were then adjusted downward by cost-
to-charge ratios.1 6    As such, it may be thought of as an estimate of long-run average cost. For any 
given hospital, the savings from averting infections is likely to be substantially less and will depend, for 
example, on staffing flexibility and the value of alternative uses for the freed-up bed-days. 1 7• 1 8 
Nevertheless, the cost-savings of the universal decolonization strategy should be realized even by 
those institutions with excess capacity or staffing that is hard to reduce in the short term. Even when 
using a very conservative estimate of variable costs (one not including any labor costs), universal 
decolonization still dominates the other 2 strategies. We note also that our analysis is otherwise 
conservative in that we have not included any productivity or time costs associated with reduced 
morbidity. 
In addition, because overall intervention costs were similar or lower in our base case estimates, the 
universal decolonization strategy was the most cost-saving strategy, even under assumptions of minimal 
effect in reducing BSis compared with screening and isolation alone. 
The effectiveness estimates for the prevention strategies were derived from a single trial that 
included mostly com- munity hospitals, although they were largely representative of US hospitals. 9 
Results could vary in hospitals with different patient characteristics, such as proportion of MRSA 
carriage, or different BSI rates. (The REDUCE MRSA trial focused on community hospital ICUs that 
may have lower BSI rates than ICUs in academic or specialty cancer care hospitals.) Nevertheless, 
our sensitivity analyses indicate that the results were robust to changes in those parameters. We did 
not measure the absolute savings of each strategy compared with no intervention. Among the 
  
TABLE 5. Sensitivity Analyses of  Cost  Savings of  3  Intensive  Care  Unit  (ICU)  Strategies  to  Reduce  ICU  Bloodstream  Infection  per 
1,000  ICU Admissions 
Cost (saving) 
per  admission of 
universal decolonization , $US 
 
Scenario  number  and description 
Compared with 
screening and isolation 
Compared with 
targeted  decolonization 
Base case 
One-way sensitivity 
I.  Assume  MRSA screening  is done  using  polymerase  chain  reaction  test ($48) 
2. Assume  use  of  trade  mupirocin ($94) 
3. Assume  time  to don  and doff gloves and gown is 2 minutes 
4. Assume 30 nurse and 6 physician  visits per ICU-day 
5. Assume no incremental  labor costs associated  with contact precautions 
6. Assume 20% of patients arriving at ICU under screening and isolation and 
targeted decolonization strategies have history of MRSA and are placed on 
contact precautions 
7. Assume 5% of patients arriving at ICU under screening and isolation and 
targeted decolonization strategies have history of MRSA and are placed on 
contact precautions 
8. Assume I0.8% of patient s arriving at ICU under  universal decolonization 
have history of MRSA and are placed on contact precautions (ie, the same 
percent  as for the other strategies) 
9. Assume incremental cost of bloodstream infection is $2,880 (estimate of 
short-run  variable costs) 
IO.  Assume incremental cost of bloodstream infection is $35,000 
11. Assume relative risk of bloodstream infection in universal decolonization 
strategy compared with screening and  isolation  strategy  is  0.4912  (rather 
than 0.5612) 
12. Assume relative risk of bloodstream infection in universal decolonization 
strategy compared with screening and isolation strategy  is 0.6512 (rather 
than 0.5612) 
Multiway sensitivity 
MI. Include only those  costs  estimated  to  be short- run  variable  costs  (scenarios  
5  and 9) 
M2. Combine assumptions least favorable to universal decolonization strategy 
(scenarios  2, 5, 8, 9, and 12)' 
M3. Combine assumptions most favorable to universal decolonization strategy 
(scenarios  I, 4, 6, IO, and 11 ) 
(171) (100) 
 
(210) (140) 
(85) (23) 
(190) (119) 
{151) (80) 
(153) (82) 
(228) (160) 
 
 
(134) (60) 
 
 
(128) (57) 
 
 
(41) (34) 
 
(299) {166) 
(196) (125) 
 
 
(140) (69) 
 
 
 
(23) (16) 
 
94 92 
 
(507) (367) 
 
 
NOTE. Data differ from those given in the text due to rounding; data in  parentheses are savings.  MRSA,  methicillin-resistant  Staphylococcus 
aureu s. 
'  Scenario  7  was excluded  because  it  was considered  implausible  for  the  universal decolonization strategy  to  have  a higher  percentage of  
patients on  contact  precaution s given  that  no  MRSA  testing  is performed  in  this strategy. 
 
hospitals in the REDUCE MRSA trial, screening and isolation was the longstanding gold standard, I2 
and that is the strategy to which the other strategies were compared. Any gains attained by screening 
and isolation before the baseline period were not quantified.  Nevertheless, the cost savings of the 
universal decolonization arm over screening and isolation alone and targeted decolonization is valid. 
Because we used a static model, we could not explicitly account for possible changes in resistance or 
herd effects. However, the results of the trial upon which our base case epidemiological assumptions 
were based incorporated those effects to the extent that they occurred during the period of the trial. 
The use of a static model also meant that sensitivity analyses (for example, those in which the 
incidence of BSis were varied) were not dynamically linked to other parameters, such as MRSA 
carriage rates, to which they might, in actuality, be related. 
Widespread and long-term use of chlorhexidine and mupirocin may engender  drug  resistance.1 9• 2  ° 
From  the perspective of this study, increased resistance would be tantamount to reduced 
effectiveness of universal decolonization. However, the effect of universal decolonization on 
 reducing BSis does not need to be large for that strategy to be preferred. Finally, our perspective 
was primarily that of the healthcare system and resource use, and so we did not address issues 
relating  to  hospital reimbursement. 
A strategy of universal decolonization for patients admitted to the ICU would both reduce BSis and 
likely reduce health- care costs compared with strategies of MRSA nares screening and isolation or 
screening and isolation coupled with targeted decolonization. These findings were robust to a wide 
range of cost and effectiveness assumptions. 
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